ClinicalTrials.gg
CompletedNCT05320094Updated Nov 8, 2022

A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants

A Phase 1 interventional study of Mavacamten and Activated Charcoal with Sorbitol in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Anthrax with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Anthrax · United States.

Enrollment
29th of 40
45 · median 97
Started
2022
with 1 other
Phase 1
23 of 47
none open now
Registered
43rd of 47
by date
Lead sponsor
1 of 47
Bristol-Myers Squibb

Among the 47 studies in Anthrax with a site in United States, this one is the 29th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2022, is one of 23 in phase 1, and was the 43rd registered.

Anthrax

75 studies on the registry are indexed under Anthrax; 12 are open to participants now.

Browse Anthrax studies →

Open to participants now

1 of the 47 studies in Anthrax with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Anthrax studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Anthrax with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of co-administration of activated charcoal with sorbitol on the single-dose drug levels of mavacamten in healthy participants.

03

Conditions studied

  • Healthy Participants

Browse trials for

Keywords

  • Mavacamten
  • Sorbitol
  • Activated Charcoal
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 18 and 30 kg/m\^2, inclusive, at the Screening Visit
  • Healthy, as determined by physical examination, vital signs, (ECGs), and clinical laboratory assessments

Exclusion criteria

Exclusion Criteria:

  • Current or recent (within 3 months of study intervention administration) gastrointestinal disease
  • History of sorbitol or fructose intolerance or inability to tolerate activated charcoal
  • History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Drug: Mavacamten

  • Experimental
    Mavacamten and activated charcoal with sorbitol - Dose A

    Drug: Mavacamten · Drug: Activated Charcoal with Sorbitol

  • Experimental
    Mavacamten and activated charcoal with sorbitol - Dose B

    Drug: Mavacamten · Drug: Activated Charcoal with Sorbitol

Interventions

  • Specified dose on specified days

  • DrugActivated Charcoal with Sorbitol

    Drug pages: Charcoal · Sorbitol

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve from time zero extrapolated to infinite time ((AUC(INF))

    Time frame: Up to 2 months

  2. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration ((AUC(0-T))

    Time frame: Up to 2 months

  3. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 1 month

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 3 months

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 3 months

  3. Number of participants with vital sign abnormalities exceeding predefined thresholds

    Time frame: Up to 3 months

  4. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 3 Months

  5. Number of participants with physical exam abnormalities

    Time frame: Up to 3 months

  6. Number of participants with clinical laboratory evaluation abnormalities

    Time frame: Up to 3 months

  7. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 1 month

  8. Apparent terminal plasma half-life (T-HALF)

    Time frame: Up to 2 months

  9. Concentration at 24 hours (C24)

    Time frame: Up to 1 month

07

Study locations

1 site
  • Local Institution - 0001
    Dallas, Texas 75247-4989, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Sep 2022, 4 months.

Of 11 phase 1 interventional studies under Anthrax, half reached primary completion within 14 months of starting (the median); a quarter within 8 and three quarters within 18. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 11, 2022
StartActual
Apr 15, 2022
Primary completionActual
Sep 11, 2022
CompletionActual
Sep 11, 2022
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05320094
Responsible party
Sponsor
First posted
Apr 11, 2022
Start date
Apr 15, 2022
Primary completion
Sep 11, 2022
Completion
Sep 11, 2022
Last update
Nov 8, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion